# Tirzepatide Legit — Independent verification reference for FDA-approved tirzepatide > An editorial reference on what makes tirzepatide legitimate: the FDA-approved supply chain, NDC and barcode verification, and the regulatory status of compounded copies after the October 2024 shortage resolution. A plain-language reference for distinguishing the FDA-approved tirzepatide product from compounded, repackaged, and import 'research-only' versions. Editorial only. No products sold, no clinics affiliated. ## The short version: what 'legit' means here Tirzepatide is a dual GIP/GLP-1 receptor agonist — a single 39-amino-acid peptide that activates two gut-hormone pathways at once. The FDA has approved it for type 2 diabetes, chronic weight management, and obstructive sleep apnea with obesity. Only one authorized supply chain carries that approval. What that means in practice: any pen, vial, or powder labeled as tirzepatide that did not originate from that supply chain is, in the FDA's regulatory terms, an unapproved product — regardless of what it says on the label or who is selling it. The clinical trial data on weight loss, blood sugar control, and cardiovascular outcomes was generated for the approved product. None of it applies automatically to compounded copies, repackaged vials, or import 'research peptide' powders. This site exists to help readers understand the distinction. It is an editorial reference on the regulatory and analytical record. [See what people report on the effects page.](/effects) ## What 'legit' means here Tirzepatide is a single 39-amino-acid peptide approved by the U.S. Food and Drug Administration for three indications: type 2 diabetes (May 2022), chronic weight management (November 2023), and moderate-to-severe obstructive sleep apnea in adults with obesity (December 2024) [1][2][3]. Only one pharmaceutical manufacturer holds those approvals. Any pen, vial, or vial-and-syringe kit labeled as tirzepatide that did not originate from that authorized supply chain is, in FDA's terms, an unapproved product. That distinction is narrower and stricter than it sounds. It is not a moral judgment about who is selling what. It is a regulatory statement: the FDA has reviewed the identity, purity, potency, sterility, and clinical evidence for exactly one tirzepatide product line. Everything else — compounded copies from state-licensed pharmacies, bulk-compounded lots from outsourcing facilities, repackaged vials, gray-market imports, and online 'research peptide' powders — sits outside that review. This site exists to help readers tell those categories apart. It is not a clinic. It does not sell, recommend, or arrange the purchase of any product. It is editorial commentary on the publicly available record. ## What changed in late 2024 From December 2022 through most of 2024, the FDA listed tirzepatide injection as being in shortage. That listing carried a specific regulatory consequence: under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, state-licensed pharmacies and FDA-registered outsourcing facilities are normally barred from compounding copies of an FDA-approved drug, but a shortage listing creates a narrow exemption [4]. On October 2, 2024, the FDA removed tirzepatide from the shortage list. Industry litigation followed; the agency reaffirmed the decision in a December 19, 2024 declaratory order [4]. Enforcement discretion ended on February 18, 2025 for 503A state-licensed pharmacies and on March 19, 2025 for 503B outsourcing facilities. Since those dates, compounded tirzepatide is no longer permitted under the shortage exemption, with very narrow exceptions for documented patient-specific medical need. A pharmacy that continues to compound tirzepatide for routine weight-loss or diabetes use is operating outside the federal compounding framework. That is the regulatory backdrop against which the word *legit* now has to be read. ## What an FDA-approved supply chain looks like A legitimate dispense path has six recognizable features [13]: 1. A valid prescription issued by a U.S.-licensed prescriber after a real clinical evaluation. 2. A U.S. state-licensed pharmacy that purchases from the authorized U.S. distribution chain. 3. The original manufacturer carton with intact tamper-evident seals, a printed lot number, a National Drug Code (NDC), and an expiration date that matches the contained pen or vial. 4. A 2D data matrix on the carton that scans successfully on the manufacturer's verification portal [13]. 5. An NDC that validates in the FDA NDC Directory. 6. Cold-chain handling — 2 to 8 degrees Celsius from manufacturer through dispensing. If any of those six are missing, the product is, at minimum, unverified. That does not by itself prove counterfeit or harmful. It means the chain of custody that the FDA review depends on cannot be reconstructed. ## What unapproved sources have looked like in practice The post-shortage period has produced an unusually rich documentary record on what goes wrong with non-FDA-approved tirzepatide. The Food and Drug Administration has logged more than 1,150 adverse-event reports tied to compounded GLP-1 and dual-agonist drugs as of July 31, 2025 [11]. Many involve dosing errors traced to multidose vials filled with patient-drawn syringes — a delivery format that the FDA-approved product, supplied in single-dose pens or single-dose vials, was specifically designed to avoid [10]. Analytical chemistry has added its own layer. Laboratory testing of seized and purchased non-FDA-approved tirzepatide samples has documented bacterial contamination, elevated endotoxin levels, off-target impurities, and mismatched potency — some lots above 100 percent of label claim, others below 50 percent, and some containing no tirzepatide at all [12]. A 2026 preprint identified a previously uncharacterized B12-tirzepatide adduct in mass-compounded tirzepatide-B12 mixtures [12]. Federal litigation and U.S. International Trade Commission proceedings (Inv. No. 337-TA-1429) have named multiple importers and clinics in the United States, Spain, and China for distributing knockoff tirzepatide products falsely labeled as FDA-approved, as having passed clinical trials, or — in some cases — as containing tirzepatide at all when chemistry analysis showed they did not [16]. These are not theoretical concerns. They are the documentary residue of an active enforcement period. ## Why the molecule itself rewards verification Tirzepatide is a 4,813 dalton, 39-amino-acid linear peptide built on the native GIP scaffold, with two alpha-aminoisobutyric acid residues at positions 2 and 13, a C-terminal amide, and a C20 fatty diacid attached via a gamma-Glu-2xAEEA linker to lysine 20 to enable albumin binding [7]. That structure is what produces dual GIP and GLP-1 receptor agonism with the specific biased-signaling fingerprint observed in cell-based assays — native-like GIP receptor affinity (Ki around 0.135 nM), roughly 18 to 20-fold weaker GLP-1 receptor binding than native GLP-1, and a preference for cAMP signaling over beta-arrestin recruitment [6]. Cryo-EM structural work has resolved the dual-receptor engagement mode in detail [9]. The point for verification is narrow: a product that is not the exact 39-mer with that exact fatty-acid conjugation does not reproduce that pharmacology. *Tirzepatide* is, chemically, a specific molecule. *A peptide that someone has labeled tirzepatide* is a marketing claim. --- An editorial reference on the regulatory and analytical record — not a clinic, not a vendor, not a prescription.